North America Botulinum Toxin Market 2023-2030

North America Botulinum Toxin Market 2023-2030

Market Outlook

Triton Market Research’s report states that North America botulinum toxin market is deemed to garner a compound annual growth rate of 9.78% over the forecasting years from 2023 to 2030. Canada and the United States are studied in the given region.

In the US, the growing popularity of cosmetic treatments and product approvals widens the scope of the botulinum toxin market. For instance, Evolus Inc garnered approval from the FDA for Jeuveau for the temporary enhancement of the appearance of moderate to severe glabellar lines in adults linked to the activity of the corrugator and procerus muscles. Moreover, the FDA sanctioned the specific indications requiring Botox injections to address frown lines, crow’s feet, and horizontal forehead lines.

Furthermore, according to estimates, Canada hosts a skilled workforce of aesthetic surgeons who play a key role in the botulinum toxin market’s expansion. Besides this, strategic initiatives have elevated the market scope in recent years. For instance, Evolus Inc and Clarion Medical Technologies, a prominent Canadian provider of medical and aesthetic equipment and consumables, launched the shipment of Nuceiva (prabotulinumtoxinA) to Canada.
Competitive Outlook
The major enterprises in the botulinum toxin market are Evolus Inc, Galderma SA, Ipsen Pharma, US WorldMeds LLC, and AbbVie Inc.